Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Amphastar Pharmaceuticals (AMPH) Depreciation & Amortization (IS) (2024 - 2025)

Amphastar Pharmaceuticals has reported Depreciation & Amortization (IS) over the past 2 years, most recently at $14.3 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (IS) at $14.3 million for Q4 2025, up 6.74% from a year ago — trailing twelve months through Dec 2025 was $56.7 million (up 7.04% YoY), and the annual figure for FY2025 was $56.7 million, up 7.04%.
  • Depreciation & Amortization (IS) for Q4 2025 was $14.3 million at Amphastar Pharmaceuticals, up from $14.1 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (IS) for AMPH hit a ceiling of $14.6 million in Q2 2025 and a floor of $13.0 million in Q1 2024.